Home

Venous stent recall

Recall notification - Venovo. ™. Venous Stent System. Bard Peripheral Vascular, Inc., a wholly owned subsidiary of Becton, Dickinson and Company (BD), has expanded the scope of the Urgent Medical Device Safety Notice issued on January 13, 2021 (the Safety Notice) for the Venovo ™ Venous Stent System to include all sizes and lots. Class 2 Device Recall VENOVO Venous Stent System. Reports of the proximal end of the stent not immediately expanding upon deployment and remaining connected to the delivery system. On 01/13/2021, the firm sent an URGENT MEDICAL DEVICE SAFETY NOTICE via FedEx to customers informing them that the Recalling Firm has received reports regarding. Class 1 Device Recall VICI VENOUS STENT System. Product Usage: is intended for the treatment of obstructions and occlusions in the venous vasculature. Boston Scientific initiated the recall by letter on April 12, 2021. The letter requested the consignee cease use and further distribution of the affected product, segregate and return to Boston. The FDA has identified Boston Scientific's recall of two venous stent systems as class I, the most serious type of recall, due to risk for stent migration that may cause injury or death

Recall Notification - Venovo™ Venous Stent System - B

Boston Scientific has recalled the VICI SDS and VICI RDS Venous Stent Systems due to the potential for stent migration from the location of original implantation. The stent systems are used to treat obstructions and occlusions in narrowed or blocked venous veins Boston Scientific's pursuit of the venous stent opportunity has suffered a setback. The company is recalling all 31,798 Vici SDS and Vici RDS venous stent systems distributed in the U.S. between Sept. 21, 2018, shortly after it disclosed the Veniti takeover, and April 9, 2021 Boston Scientific Corporation has recalled its VICI SDS and VICI RDS venous stent systems in response to reports that the stents may migrate or move from where they are initially implanted. The US Food and Drug Administration (FDA) classified this recall as class I, the most serious type, because of the potential for serious injury or death The Vici and Venovo venous stents Boston Scientific and BD have both initiated recalls of venous stents. According to a Food and Drug Administration (FDA) medical device recall notice posted May 21, Boston Scientific has recalled its Vici venous stent system (Vici SDS) and Vici RDS venous stent system There has been a recent increase in complaint reports in the US, on the Venovo 14mm diameter Stent associated with a failure to deploy. Reports indicate that at the time of deployment, the inner portion of the stent is sticking to the stent cushion

VICI Venous Stent™ System - Venous Therapies - Boston

Source. by Maria Fontanazza . Boston Scientific has recalled the VICI SDS and VICI RDS Venous Stent Systems due to the potential for stent migration from the location of original implantation. The stent systems are used to treat obstructions and occlusions in narrowed or blocked venous veins. The Class I recall involves 31,798 devices in the United States; the products were distributed between. Boston Scientific Corporation has recalled its VICI SDS and VICI RDS venous stent systems in response to reports that the stents may migrate or move from where they are initially implanted. The US.. The VENOUS WALLSTENT is intended to treat a narrowed vein found in the upper pelvic region down to the groin area (iliofemoral vein). The VENOUS WALLSTENT has two components: a stent made from.

Class 2 Device Recall VENOVO Venous Stent Syste

  1. istration (FDA) medical device recall notice posted 21 May, Boston Scientific has recalled its Vici venous stent system (Vici SDS) and Vici RDS venous stent system
  2. May 26, 2021—Device recalls of venous stents were recently initiated by Boston Scientific Corporation and Bard Peripheral Vascular, Inc., a wholly owned subsidiary of Becton, Dickinson and Company (BD). Boston Scientific recalled the Vici venous stent system and Vici RDS venous stent system
  3. Boston Scientific Recalls Vici Venous Stents for Migration Risk. The medical device manufacturer Boston Scientific has recalled 31,798 Vici Venous Stent Systems due to a risk of injury or death. The recalled Vici SDS and Vici RDS Venous Stent Systems are used to treat blocked veins or obstructions in narrow veins
  4. The Vici Venous Stent System (Vici SDS) and the Vici RDS Venous Stent System recalls affects 34,248 devices recalled worldwide, 31,798 of those in the United States, distributed September 21, 2018,..
  5. The FDA announced today that it deemed Boston Scientific's recall of its VICI SDS and VICI RDS venous stent systems as Class I, the most serious kind of recall. Marlborough, Mass.-based Boston..

Class 1 Device Recall VICI VENOUS STENT Syste

Medical device manufacturer Boston Scientific has recalled 31,798 Vici Venous Stent Systems because of a risk of injury or death. According to an alert issued by the U.S. Food and Drug Administration (FDA), the federal agency that regulates medical device safety, the recalled Vici SDS and Vici RDS Venous Stent Systems are used to treat blocked veins or obstructions in narrow veins Stent Length (mm) Delivery System. Delivery System Length (cm) BD Interventional. Venovo Venous Stent System. Nitinol. Open-cell. 8-10. 0.035 Vici venous stent system. According to a medical device recall notice posted on the Food and Drug Administration (FDA) website, Boston Scientific has recalled its Vici venous stent system (Vici SDS) and Vici RDS venous stent system due to reported instances of stent migration The recall covers 31,798 VICI venous stent programs distributed within the US between September 21, 2018 and April 9, 2021. On April 12, Boston Scientific despatched an pressing medical gadget recall letter to clients asking them to instantly discontinue use of the gadget; take away and safe all affected items from stock; full the corporate's.

  1. Health care providers using the VICI VENOUS STENT System and VICI RDS VENOUS STENT System 5/24/2021 Boston Scientific Corporation Recalls VICI VENOUS STENT System and VICI RDS VENOUS STENT System for Potential of Stent Migr
  2. Patients who received a Venovo™ Venous Stent had a weighted PP rate of 88.3%, demonstrating a statistically significant difference from a literature-derived performance goal (PG) of 74%, with an 81.3% PP rate for subjects with post-thrombotic syndrome and 96.9% PP rate for subjects with non-thrombotic iliac vein lesions
  3. Venous sinus stenting is a relatively new procedure and researchers are still gathering data regarding how long the procedure manages PTC and what complications may occur over time.S tenting seems to address the underlying cause of the high pressure that characterizes PTC, but the exact mechanism remains controversial
  4. Boston Scientific is recalling the Vici SDS and RDS venous stent system due to concerns that stents may migrate from where they are initially implanted. FDA said there have been 17 complaints and reported injuries related to this medical device recall, but no reported deaths. The Vici SDS and RDS venous stent systems are intended for the.

HOLLYWOOD, FL—Two-year data for two venous stents show primary patency rates of around 80% or higher, repeat revascularization rates hovering at approximately 10%, and no signs of stent fracture or movement. These results, presented at the 2020 International Symposium on Endovascular Therapy (ISET), bolster the 1-year data that informed the. The recall covers 31,798 VICI venous stent systems distributed in the US between September 21, 2018 and April 9, 2021. On April 12, Boston Scientific sent an urgent medical device recall letter to customers asking them to immediately discontinue use of the device; remove and secure all affected units from inventory; complete the company's.

FDA designates recall of two venous stent systems as class

Boston Scientific Recalls Over 30,000 Stent Systems Due to Migration Risk. FDA deemed Boston Scientific's recall of the Vici SDS and RDS venous stent systems a Class I recall, reports MDDI. Boston Scientific is recalling the Vici SDS and RDS venous stent system due to concerns that stents may migrate from where they are initially implanted Bard LifeStent Solo Vascular Stent Recall Lawsuit Information regarding injuries including bleeding, loss of limb, heart attack, vascular surgery, and death. FREE Case Review (866) 588-0600 Call Today for a FREE Confidential Case Review, Toll-Free 24/7 (866) 588-060 The FDA announced today that it deemed Boston Scientific's recall of its VICI SDS and VICI RDS venous stent systems as Class I, the most serious kind of recall. Marlborough, Mass.-based Boston Scientific's VICI SDS and VICI RDS venous stent systems treat obstructions and occlusions in narrowed or blocked venous veins BRIEF-FDA Says Boston Scientific Recalls VICI VENOUS STENT System And VICI RDS VENOUS STENT System. BY R. — 2:32 PM ET 05/21/2021. May 21 (R) - U.S FDA: * FDA - BOSTON SCIENTIFIC CORPORATION RECALLS VICI VENOUS STENT SYSTEM AND VICI RDS VENOUS STENT SYSTEM FOR POTENTIAL OF STENT MIGRATION. * FDA - IDENTIFIED RECALL OF BOSTON.

Ovation iX Abdominal Stent Graft Recalled After 5 Deaths

Boston Scientific Recalls Venous Stent System Due Device

Cook Stent Recall Lawsuit. Cook Medical Inc. has announced a recall of the Zilver PTX stent, which is used to prop open arteries in the thigh of patients with circulation problems. The recall was initiated after 13 reports of the stent catheter tip separating in a patient's body, which caused two injuries and one death Taxus Express2 Stent Recall. In March 2004, Boston Scientific received FDA approval to sell Taxus drug-eluting heart stents. Less than 6 months later, the company announced a recall of Taxus heart stents due to safety concerns. The recall eventually grew to include over 100,000 heart stents

Mary McMahon After an angioplasty procedure, some stents fail if soft tissue grows over them. Causes of stent failure can include poor placement, the use of bare metal stents, and mechanical fatigue.Success rates can vary by device and medical professional; people with substantial experience in stenting procedures, for example, can experience more positive patient outcomes The Venovo™ venous stent is a flexible nitinol stent specifically designed to reopen blocked iliac and femoral veins in order to maintain adequate blood flow. The Venovo™ venous stent is designed with a balance of radial strength, compression resistance and flexibility needed for the treatment of symptomatic post-thrombotic and non.

Boston Scientific is recalling the VICI SDS and RDS VENOUS STENT Systems after reports indicate that the stents may migrate or move from where they are initially implanted. A migrated stent may require another surgery or catheter procedure to retrieve it, which increases risks to the patient, including possible damage to the blood vessel, heart. The FDA has designated Endologix' recall of an abdominal stent graft system as a class 1 recall, the most serious kind. The recall affects 5,403 devices (Ovation iX Abdominal Stent Graft Systems. FDA Recalls Boston Scientific Vici Venous Stent & Vici RDS Venous Stent Systems Hey everybody, not to post with a disheartening title, but as someone with May Thurner's, was feeling a bit overwhelmed with Boston Scientific's recall of the Vici stents, as I've had three placed- two last year and one in December Abre Venous Self-expanding Stent System. The Abre™ venous self-expanding stent system is designed for the unique challenges of venous disease. It offers easy deployment, to let physicians focus on their patient, and delivers demonstrated endurance, to give patients freedom of movement. 1,2 Contact U

Boston Scientific and BD initiate venous stent recalls. Boston Scientific and BD have both initiated recalls of venous stents. According to a US Food and Drug Administration (FDA) medical device recall notice posted 21 May, Boston Scientific has recalled its Vici venous stent system (Vici SDS) and Vici RDS venous stent system Medtronic Vascular has issued a recall for certain models of its Angiographic Guidewire Component, used during angiography and interventional procedures, because the devices weren't sterilized.

Boston Scientific recalls venous stents because of migration risk. medtechdive.com - By • 3d. Dive Brief: Boston Scientific is recalling all Vici SDS and Vici RDS venous stent systems distributed over a 30-month period in light of 17 complaints Read more on medtechdive.com. 135 cm Catheter Working Length. Indications: 1 = Tracheobronchial, 2 = Transjugular Intrahepatic Portosystemic Shunt (TIPS), 3 = Transhepatic Biliary, 4 = Iliac, 5 = Venous. The C-code used for this product is C1876, Stent, non-coated/non-covered with delivery system. C-codes are used for hospital outpatient device reporting for Medicare and. Spine surgery. Bypass surgery. If a loved one has suffered an injury due to an unnecessary surgical procedure or leg stent, and have questions about the legal remedies available to improve quality of life and medical care, contact The Lyon Firm at (800) 513-2403. You will speak directly with Mr. Lyon, a Cincinnati medical malpractice attorney. Excessive oversizing of stents has been reported to contribute to post-operative patient pain. The stented length should be at least 1cm longer than the obstructive venous lesion (a minimum of 0.5cm centrally and 0.5cm peripherally). Stent Deployment: The VICI VENOUS STENT cannot be recaptured into the delivery system once it is partially.

According to a Food and Drug Administration (FDA) medical device recall notice posted May 21, Boston Scientific has recalled its Vici venous stent system (Vici SDS) and Vici RDS venous stent system. In a recall notification dated May 12, BD announced that the company has expanded a safety notice issued earlier this year for the Venovo venous. Dive Brief: Boston Scientific said Monday it received FDA approval for the Vici Venous Stent system, which the medtech giant acquired in August 2018 as part of its takeover of Veniti.; The self-expanding nitinol device, used to treat iliofemoral venous obstructive disease where a blood clot or compressed vein can cause blood to pool in the legs and cause pain, swelling and skin ulcers, seeks. The LifeStent Solo Vascular Stent is a self-expanding stent and delivery system used to improve the inner open space of blood vessels in the treatment of lesions caused by the abnormal narrowing of blood vessels. On September 30, 2013, the FDA issued a Class I recall, which is the most serious type of recall

Boston Scientific recalls venous stents because of

FDA Class I Recall of Some Boston Scientific Venous Stents

  1. al veins that drain the leg circulation. Usually the stents are placed in the pelvic veins above the groin skin crease, but sometimes the lower tip of the stent may extend below the groin into the thigh veins
  2. al diameter in the iliofemoral veins for the treatment of symptomatic iliofemoral venous outflow obstruction
  3. Vein stenting is a procedure that places a metal tube-like structure within the vein to keep the vein open and allow for appropriate blood flow. This procedure is commonly performed on the heart, but is also performed routinely on the veins in the legs. Let's explore what type of venous conditions may require a stent and how the stents are.
  4. Boston Scientific recall stents following 17 complaints. Following 17 complaints, Boston Scientific has moved to recall all of its Vici SDS and Vici RDS venous stents over a risk of them moving from where they are initially implanted. This migration risk could lead to the need for procedures or even life-threatening injuries
  5. The vascular stents industry is rife with timely innovation and lifesaving technology. However, strict regulations and high probability for product recall do pose a serious challenge
  6. Boston Scientific stent recall is Class I May 21, 2021 By Sean Whooley The FDA announced today that it deemed Boston Scientific's recall of its VICI SDS and VICI RDS venous stent systems as.
  7. al diameter of a blood vessel (peripheral artery and/or vein) and, alternatively, the tracheobronchial tree; it may in addition be intended to be used in the biliary tract

Boston Scientific and BD initiate venous stent recalls

Iliofemoral vein stent A non-bioabsorbable tubular device intended to be implanted in an iliac and/or femoral vein to maintain patency in patients with constrained venous outflow. It is inserted and advanced to the site of implantation with a dedicated catheter where it self-expands upon release The FDA approved the Zilver PTX drug-eluting stent for peripheral artery disease in November. Surgeons and vascular specialists had been waiting for the availability of this product in the United States for quite some time. VDM interviewed Gary Ansel, MD, on the FDA approval of the stent. Dr Stents that are covered with drugs to prevent an artery from re-narrowing are called drug-eluting stents. Stents without a drug coating are called bar-metal stents. About the Absorb G1 BVS System. The Absorb G1 BVS Stent was the first and only fully dissolving, drug-eluting stent ever approved to treat patients with coronary artery disease DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™ thoracic stent graft system and informed physicians to immediately cease use of the device until further notice.. In accordance with its commitment to patient safety - and in consultation with independent. A peripheral vascular stent placement is a procedure to widen a narrowed artery in your leg or arm. A stent is a wire mesh tube that helps hold your artery open. Some stents have medicine that helps prevent blockages in your artery. How do I prepare for a peripheral vascular stent placement

VENOVO VENOUS STENT SYSTEM (2021-01-18) - Recalls and

FDA Class I Recall of Some Boston Scientific Venous Stent

  1. The VICI VENOUS STENT and VICI VERTO VENOUS STENT were developed specifically for the challenges of treating iliofemoral venous outflow obstruction. VENITI was founded in 2010 and is headquartered.
  2. gton, Ind. - Cook Medical today announced that the Zilver® Vena™ Venous Self-Expanding Stent is commercially available to physicians in the United States. Zilver Vena is a self-expanding stent designed to meet the needs of patients suffering from symptomatic iliofemora
  3. Vascular Stent Market business report is a trustworthy source of market information for the business which assists with better decision making and outline better business strategies

The good news is that while this recall will create a bit of a dent in the Zilver PTX's 2013 global sales, it's unlikely to affect the 2017 projection. This is publicity that Cook Medical can ultimately get past the problem is with the delivery system rather than the stent itself, which is a plus Venous Stents market is expected to grow at a CAGR of 9% from 2021-2027 to exceed US$ 2 billion by 2027. Request Sample Copy of this Report @ https://bit.ly/3hGU7W The FDA issued a class 1 recall of Bard Peripheral Vascular Inc.'s LifeStent Solo Vascular Stent, an implantable self-expanding stent and delivery system, as a result of deployment complications including failure to deploy, partial deployment, and difficult deployment

The FDA has issued safety information regarding a Class 1 recall of Bard LifeStent Solo Vascular Stent. The product has been recalled due to deployment issues that range from failure to deploy, partial deployment, and difficult deployment. The consequences of product failure include possible complications of bleeding, loss of limb, heart attack. ICYMI: The @US_FDA has identified Boston Scientific's #recall of two venous stent systems as class I, the most serious type of recall, due to risk for stent. The recall was initiated due to reports of stent fractures and endoleaks. Thus far, there have been 11 reported issues, including 4 cases of Type III endoleak, 4 cases of stent fracture, and 7. The reason for the recall is a potential failure to deploy the stent, which would have potentially serious adverse health consequences. Background The LifeStent Solo Vascular Stent is an implantable self-expanding stent and delivery system used to improve a peripheral blood vessel's luminal diameter in the treatment of lesions caused by the.

Background: Although stent implantation is used worldwide for peripheral arterial disease, there is little data on the safety and long-term patency of stents implanted for venous disease. Methods and results: We studied 13 patients with 14 lesions (6 males, 7 females, mean age: 63.2±10.2 years) diagnosed with venous stenosis and who underwent venous stenting Use: The LifeStent Solo Vascular Stent is an implantable self-expanding stent and delivery system used to improve the inner open space of a blood vessel (luminal diameter) in the treatment of lesions caused by the abnormal narrowing in a blood vessel (symptomatic de-novo or restenotic lesions). Recalling Firm: Bard Peripheral Vascular Inc

Venous Wallstent - P980033/S050 Fd

--Medtronic plc, the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™ thoracic stent graft system and informed physicians to. Customer inquiries related to this recall, as well as adverse reaction/events experienced with the product should be addressed to BD Customer Support at 1-844-8BD- LIFE (1-844-823-5433); When calling Monday- Friday between the hours of 9 a.m. to 6 p.m. ET, say Recall when prompted.For additional information, customers can visit www.bd-chloraprep-action.com Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction Abre(TM) Venous Self-Expanding Stent System Safe, Effective in Treating Challenging Deep Venous Lesion

Peripheral Vascular Devices Market, by Product, 2013. Various types of stents such as a drug-eluting stent, a bare-metal stent, a bio-absorbable stent, covered stent, a dual-therapy stent, or bioengineered stent are available in the market The 2,6404 patients randomized in the trial to Absorb or a Xience everolimus-eluting stent showed noninferiority for the primary endpoint of 30-day target lesion failure (5.0% versus 3.7%, P=0.02. Reopen and regenerate: Exosome-coated stent heals vascular injury, repairs damaged tissue. Exosomes (magenta) released from a stent in the blood vessel. Credit: Cheng Lab. Researchers from North. Angioplasty and stent placement - peripheral arteries. Angioplasty is a procedure to open narrowed or blocked blood vessels that supply blood to your legs. Fatty deposits can build up inside the arteries and block blood flow. A stent is a small, metal mesh tube that keeps the artery open. Angioplasty and stent placement are two ways to open.

UVA | Physician Resource

Moreover, iliac venous stenting in patients with active venous ulcer disease has also been reported.1, 5, 6, 7. The purpose of this study was to analyze patients suffering from advanced CVD, without active venous ulcer disease, with NIVLs and who underwent iliac vein stenting at our vascular center GORE-TEX ® Vascular Graft has long been the prosthetic of choice among vascular surgeons worldwide. GORE-TEX® Suture The GORE-TEX® Suture is a microporous, monofilament suture of flexible biomaterial for excellent handling, reduced hole-leakage, and minimal irritation in soft tissue approximation The S.M.A.R.T.® Vascular Stent System is indicated for use to improve luminal diameter in the treatment of patients with de novo or restenotic native lesion (s) of the superficial femoral artery and/or proximal popliteal artery with total length up to 150mm and with a reference vessel diameter ranging from 4mm to 7mm. Patients who cannot.

From the 8-K: The Company is providing the following additional details related to its voluntary global recall of its Valiant Navion™ Thoracic Stent Graft System. Medtronic does not expect this. Fisheye Over Sinai. Astronaut Andrew Morgan shot this wide-angle photograph from the central Cupola window of the International Space Station (ISS) in August 2019. The Soyuz capsule and the Canadarm2 frame this image of the southeastern Mediterranean coastline. The 16 mm fisheye lens, though infrequently used, allows for a unique view. Resolute Onyx DES. Resolute Onyx™ DES offers flexibility, conformability, deliverability, and visibility in a 2.0-5.0 size matrix. See what makes Resolute Onyx DES different. Indications, Safety, and Warnings. Product Details Frequent product recalls by key market players is likely to hamper the growth of the DES market. For instance, in November 2017, Boston Scientific initiated a voluntary recall for its 150mm Eluvia drug eluting vascular stent, as well as its 180mm and 200mm Innova self-expanding stent system due to growing number of issues registered for partial. Piazza M, Squizzato F, Dall'Antonia A, et al. Outcomes of self expanding PTFE covered stent versus bare metal stent for chronic iliac artery occlusion in matched cohorts using propensity score modelling. European Journal of Vascular & Endovascular Surgery 2017;54(2):177-185

by Vascular Disease Management. Reply. Zilver PTX; Cook Medical. This week, Cook Medical announced that due to a problem with the delivery system for its Zilver PTX stent, just approved by the FDA in November of last year, the company has announced a voluntary recall of the drug-eluting stent. According to a press release, there have been 13. FMI estimates that the global market for peripheral vascular stents is expected to be valued at US$ 5,324.1 Mn by 2028 end, expanding at an impressive CAGR of 6.6% over 2018-2028. The self-expanding stents was the leading segment in the global market with above 52.1% revenue share in 2017. North America is expected to expand at healthy CAGR. The Venovo(TM) venous stent is a flexible nitinol stent specifically designed to reopen blocked iliac and femoral veins in order to maintain adequate blood flow. The Venovo(TM) venous stent is designed with a balance of radial strength, compression resistance and flexibility needed for the treatment of symptomatic post-thrombotic and non. As with any type of vascular implant, infection secondary to contamination of the stent may lead to thrombosis, pseudo aneurysm or rupture. Precautions Venous access should be available during carotid stenting in order to manage bradycardia and/or hypotension by pharmaceutical intervention or placement of a temporary pacemaker

2.1.1. Surge in the Adoption of Vascular Procedures 2.1.2. Product Recalls Owing to Safety Concerns 2.2. Impact of COVID-19 on Peripheral Vascular Devices Market 2.3. Porter's Five Forces Analysis. It was founded in 1991 and is headquartered in London.Bio-absorbable stents are gaining popularity in the peripheral vascular devices and equipment market in order to eliminate thrombogenic risk. Therefore, vascular stents with NO-releasing property and surface engineered endothelial glycocalyx molecules may provide highly biomimetic endothelial functions for the prevention of thrombosis, hyperplasia and restenosis. To this end, surface bioengineering on the implants is indispensable. Intuitively, molecular modification of vascular.